['estrogen receptor positive breast cancer']
['azd5363', 'placebo', 'fulvestrant']

        Inclusion Criteria:

          -  Post-menopausal Women

          -  Life expectancy 3 months

          -  Histological confirmation of ER+ breast cancer

          -  Clinical or histological confirmation of metastatic or locally advanced disease not
             amenable to surgical resection

          -  Measurable or non-measurable disease

          -  Adequate bone marrow, renal and hepatic function

          -  Eastern Cooperative Oncology Group (ECOG) performance status < or equal to 2

          -  Progressive disease whilst receiving an aromatase inhibitor (AI) for metastatic breast
             cancer (MBC)

          -  Relapsed with metastatic disease whilst receiving an AI in adjuvant setting

          -  Up to 3 prior lines of endocrine therapy for Advanced Breast Cancer

          -  Up to 1 line of chemotherapy for Advanced Breast Cancer

          -  Patient willing to donate archival tumour sample

          -  Patient willing to donate baseline blood sample

          -  Suitable for further endocrine therapy

        Exclusion Criteria:

          -  Previous treatment with fulvestrant or PI3K/mTOR(mammalian target of rapamycin )/Akt
             inhibitor therapy

          -  Treatment with chemotherapy, immunotherapy or targeted, biologic or tumour
             embolisation within 21 days of study drug administration

          -  Palliative radiotherapy within 7 days of study drug

          -  Clinically significant abnormalities in glucose metabolism

          -  Rapidly progressive visceral disease not suitable for further endocrine therapy

          -  Known brain or leptomeningeal metastases

          -  Any co-existing medical condition precluding trial entry including significant cardiac
             disease (to be defined in the protocol)

          -  Concomitant medication unsuitable for combination with trial medication
      